MX387092B - Particulas de dimetilfumarato y composiciones farmaceuticas de estas. - Google Patents

Particulas de dimetilfumarato y composiciones farmaceuticas de estas.

Info

Publication number
MX387092B
MX387092B MX2017016509A MX2017016509A MX387092B MX 387092 B MX387092 B MX 387092B MX 2017016509 A MX2017016509 A MX 2017016509A MX 2017016509 A MX2017016509 A MX 2017016509A MX 387092 B MX387092 B MX 387092B
Authority
MX
Mexico
Prior art keywords
particles
dimethyl fumarate
dmf
pharmaceutical compositions
fumarate particles
Prior art date
Application number
MX2017016509A
Other languages
English (en)
Spanish (es)
Other versions
MX2017016509A (es
Inventor
Andrea Trementozzi
Cheuk- Yui LEUNG
Erwin Irdam
Peter Zawaneh
Pierre Boulas
Shyam B Karki
William F Kiesman
Yiqing Lin
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of MX2017016509A publication Critical patent/MX2017016509A/es
Publication of MX387092B publication Critical patent/MX387092B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225Polycarboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5026Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2017016509A 2015-06-17 2016-06-15 Particulas de dimetilfumarato y composiciones farmaceuticas de estas. MX387092B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562181061P 2015-06-17 2015-06-17
PCT/US2016/037486 WO2016205270A1 (en) 2015-06-17 2016-06-15 Dimethyl fumarate particles and pharmaceutical compositions thereof

Publications (2)

Publication Number Publication Date
MX2017016509A MX2017016509A (es) 2018-08-16
MX387092B true MX387092B (es) 2025-03-19

Family

ID=56292916

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017016509A MX387092B (es) 2015-06-17 2016-06-15 Particulas de dimetilfumarato y composiciones farmaceuticas de estas.

Country Status (13)

Country Link
US (2) US11291642B2 (https=)
EP (1) EP3310341A1 (https=)
JP (2) JP2018517735A (https=)
KR (1) KR20180018711A (https=)
CN (1) CN107920997A (https=)
AU (2) AU2016279997B2 (https=)
CA (1) CA2989581A1 (https=)
EA (1) EA201890068A1 (https=)
HK (1) HK1254054A1 (https=)
IL (1) IL256296A (https=)
MA (1) MA42196A (https=)
MX (1) MX387092B (https=)
WO (1) WO2016205270A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016344673A1 (en) * 2015-10-28 2018-05-17 Sun Pharmaceutical Industries Limited Pharmaceutical compositions of dimethyl fumarate
CA3013472A1 (en) * 2016-02-11 2017-08-17 Biogen Ma Inc. Pharmaceutical bead formulations comprising dimethyl fumarate
CA3075720A1 (en) * 2017-10-02 2019-04-11 Novartis Ag Method for preparing a pharmaceutical product
US11318682B2 (en) 2018-04-06 2022-05-03 Hewlett-Packard Development Company, L.P. Three-dimensional (3D) object printing based on build material permeability
CA3115516C (en) * 2018-10-05 2023-04-25 Isp Investments Llc Smooth high solids film coating composition comprising water soluble cellulose ether, process for preparing the same and method of use thereof
TR201818293A2 (tr) * 2018-11-30 2020-06-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Di̇meti̇l fumarat i̇çeren geci̇kmeli̇ salim sağlayan kapsül
EP3917500A2 (en) * 2019-01-31 2021-12-08 Elektrofi, Inc. Particle formation and morphology
BR112021018496A2 (pt) * 2019-03-20 2021-11-30 Lyndra Therapeutics Inc Cápsulas e revestimento de cápsula para formas de dosagem de residência gástrica
AU2020242062B2 (en) * 2019-03-20 2025-12-11 Nortiva Bio, Inc. Coatings for gastric residence dosage forms
CN116669715A (zh) * 2020-11-18 2023-08-29 Fb-Hrs有限责任公司 含有多非利特和美西律的组合物及其应用
CA3203975A1 (en) 2020-12-03 2022-06-09 Battelle Memorial Institute Polymer nanoparticle and dna nanostructure compositions and methods for non-viral delivery
CA3216359A1 (en) 2021-04-07 2022-10-13 Battelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
US20240269084A1 (en) 2021-06-04 2024-08-15 Zim Laboratories Limited Delayed release compositions of dimethyl fumarate
US11590071B2 (en) * 2021-07-06 2023-02-28 King Abdulaziz University Injectable drug delivery implant composition and method of use thereof
AU2024353375A1 (en) 2023-09-29 2026-04-09 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
WO2025090498A1 (en) * 2023-10-23 2025-05-01 Isp Investments Llc Encapsulated medium chain fatty acid salts and oral solid dosage forms derived therefrom
WO2025122954A1 (en) 2023-12-08 2025-06-12 Battelle Memorial Institute Use of dna origami nanostructures for molecular information based data storage systems
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2725623A1 (fr) 1994-10-18 1996-04-19 Flamel Tech Sa Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
DE19853487A1 (de) 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
IL133196A0 (en) 1999-11-29 2001-03-19 Yissum Res Dev Co Gastroretentive controlled release pharmaceutical dosage forms
DE10101307A1 (de) * 2001-01-12 2002-08-01 Fumapharm Ag Muri Fumarsäurederivate als NF-kappaB-Inhibitor
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
PL2316430T3 (pl) 2004-10-08 2012-11-30 Forward Pharma As Kompozycje farmaceutyczne o kontrolowanym uwalnianiu, zawierające ester kwasu fumarowego
EP2997953B1 (en) 2006-01-18 2018-12-26 Intec Pharma Ltd. Delivery device for oral intake of an agent
CN102149369B (zh) 2008-04-18 2016-08-10 因泰克制药有限公司 卡比多巴/左旋多巴胃滞留给药
EP2379062A1 (en) * 2009-01-09 2011-10-26 Forward Pharma A/S Pharmaceutical composition comprising one or more fumaric acid esters
CN102369001A (zh) 2009-01-09 2012-03-07 前进制药公司 包含溶蚀骨架中的一种或多种富马酸酯的药物制剂
KR20150080037A (ko) * 2011-06-08 2015-07-08 바이오젠 엠에이 인코포레이티드 고순도 및 결정질 다이메틸 푸마레이트의 제조 방법
WO2013076216A1 (en) * 2011-11-24 2013-05-30 Synthon Bv Controlled release particles comprising dimethyl fumarate
CN114146081A (zh) * 2012-02-07 2022-03-08 比奥根玛公司 含有富马酸二甲酯的药物组合物
WO2015042294A1 (en) * 2013-09-18 2015-03-26 Xenoport, Inc. Nanoparticle compositions of dimethyl fumarate
IN2013MU03070A (https=) * 2013-09-25 2015-07-17 Glenmark Pharmaceuticals Ltd
US10172794B2 (en) * 2013-12-13 2019-01-08 Biogen Ma Inc. Controlled release dosage form for once daily administration of dimethyl fumarate
ES2713157T3 (es) * 2014-02-28 2019-05-20 Banner Life Sciences Llc Cápsulas blandas entéricas de liberación controlada de ésteres de fumarato

Also Published As

Publication number Publication date
AU2016279997B2 (en) 2021-10-21
MA42196A (fr) 2018-04-25
KR20180018711A (ko) 2018-02-21
MX2017016509A (es) 2018-08-16
EP3310341A1 (en) 2018-04-25
AU2016279997A1 (en) 2018-01-18
HK1254054A1 (zh) 2019-07-12
IL256296A (en) 2018-02-28
US20220362195A1 (en) 2022-11-17
JP2022042512A (ja) 2022-03-14
EA201890068A1 (ru) 2018-09-28
AU2022200155A1 (en) 2022-02-10
WO2016205270A1 (en) 2016-12-22
CN107920997A (zh) 2018-04-17
JP2018517735A (ja) 2018-07-05
CA2989581A1 (en) 2016-12-22
US11291642B2 (en) 2022-04-05
WO2016205270A8 (en) 2017-01-19
US20190070143A1 (en) 2019-03-07

Similar Documents

Publication Publication Date Title
MX387092B (es) Particulas de dimetilfumarato y composiciones farmaceuticas de estas.
PH12018501281A1 (en) Human immunodeficiency virus neutralizing antibodies
ZA201903932B (en) Imidazopyrazine inhibitors of bruton's tyrosine kinase
MX2022009148A (es) Composiciones y metodos para el tratamiento de hemoglobinopatias.
PH12016501873A1 (en) Anti-influenza b virus hemagglutinin antibodies and methods of use
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
EP3506944A4 (en) COMPOSITIONS AND METHODS FOR TREATING TUMOR SUPPRESSOR-DEFICIENT CANCER
EP3302977C0 (en) COATING DEVICE
IL255831A (en) Inhibitors of bruton's tyrosine kinase
EP3400815A4 (en) GESCHMACKSINHALATOR
EP3328333A4 (en) SYSTEMS AND METHODS FOR CORNEAL IMPLANTS
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
EA201991431A1 (ru) УСИЛЕННЫЙ ОПОСРЕДОВАННЫЙ ТРАНСПОЗОНАМИ СЕМЕЙСТВА hAT ПЕРЕНОС ГЕНОВ И АССОЦИИРОВАННЫЕ КОМПОЗИЦИИ, СИСТЕМЫ И СПОСОБЫ
EP3380596C0 (en) COATING SOLUTIONS, COATINGS FORMED THEREFROM AND COATED MEDICAL DEVICES
MA52253A (fr) Formulation de poudre nasale pour le traitement de l'hypoglycémie
ZA201903694B (en) Inhibitors of bruton's tyrosine kinase
EP3645492C0 (en) Preparation process of ortho alkoxy bisphenol monomers
MX383931B (es) Compuestos de aza-piridona y usos de estos.
IL259669B (en) Combination products for the treatment of rsv
MA42423A (fr) Procédé de préparation d'un revêtement
EP3687940A4 (en) SELF-ASSEMBLY PROCESSES TO FORM HEDGEHOG-SHAPED PARTICLES
EA201791113A1 (ru) Фармацевтические составы в виде гранул, содержащие диметилфумарат
EP3493823C0 (en) POSTBIOTIC BASED COMPOUND FOR THE TREATMENT OF OCULAR INFLAMMATION
EA201891803A1 (ru) Фармацевтические составы в форме гранул, содержащие диметилфумарат
EP3546439A4 (en) Method for producing (z)-1-chloro-2,3,3-trifluoro-1-propene